Is NEPT a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

639 people get NEPT articles and Market Currents by email alert.

Get email alerts on NEPT »

HEADLINES:

Neptune Responds to Aker's Continued Attempts to Deflect Attention From Its Sustained Patent Infringement

GlobeNewswire (Wed, 8:30AM)
Class Action Lawsuit Against Neptune Dismissed

GlobeNewswire (Wed, 8:00AM)
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2013 Results

GlobeNewswire (May 9, 2013)
The U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation Based on Neptune & Acasti Complaint

GlobeNewswire (Apr 15, 2013)
Neptune Provides Update on European Patent Dispute and Maintains Its International Patent Strategy

GlobeNewswire (Apr 10, 2013)
Krill Oil's Omega-3s And CaPre: Brought To You By Acasti
Entry Point • Wed, Apr 3 • 19 Comments
Neptune to Present at the Annual ROTH Conference

GlobeNewswire (Mar 14, 2013)
Neptune Obtains a Third U.S. Patent on Phospholipid Compositions, Further Bolstering Neptune's Request for an ITC Investigation

GlobeNewswire (Feb 26, 2013)
Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing

GlobeNewswire (Jan 31, 2013)
Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others

GlobeNewswire (Jan 30, 2013)
Speculative Quasi-Biotech Neptune Off To A Strong Start In 2013
Zvi Bar • Tue, Jan 29 • 5 Comments
Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization

GlobeNewswire (Jan 24, 2013)
Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity
Life Sciences Report • Fri, Jan 18 • 6 Comments
Neptune Technologies & Bioresources' CEO Discusses F3Q13 Results - Earnings Call Transcript
Thu, Jan 17
Neptune Reports Third Quarter Results and Confirms First Insurance Payment

GlobeNewswire (Jan 15, 2013)
Neptune to Hold Conference Call

GlobeNewswire (Jan 14, 2013)
Neptune to Hold Conference Call

GlobeNewswire (Jan 7, 2013)
Neptune Files for Revocation of Aker's Australian Patents

GlobeNewswire (Dec 21, 2012)
Neptune Comments on Filing of Lawsuit

GlobeNewswire (Dec 20, 2012)
Neptune Gets Hammered By Shorts
Zvi Bar • Wed, Dec 19, 2012 • 7 Comments

To learn more about Seeking Alpha Pro, click here.

Speculative Quasi-Biotech Neptune Off To A Strong Start In 2013
Zvi Bar • Tue, Jan 29 • 5 Comments
Neptune Gets Hammered By Shorts
Zvi Bar • Wed, Dec 19, 2012 • 7 Comments
After Factory Explosion, A Big Retail Pump On Neptune
Richard Pearson • Mon, Dec 17, 2012 • 23 Comments
Neptune's Crisis Could Mean It's Time To Acquire This Speculative Equity
Zvi Bar • Thu, Nov 29, 2012 • 8 Comments
Neptune's Dividend Catalyst Finally In Play
M. E. Garza • Mon, Sep 10, 2012
The Future For Treating High Triglycerides: Krill Oil Neptune Style
Scott Matusow • Thu, Jul 5, 2012 • 27 Comments
Confirmation Of Anticipated Catalyst Likely To Fuel Neptune's Share Prices
M. E. Garza • Thu, Jun 28, 2012 • 4 Comments
Neptune Reports Strong Sales Growth Ahead Of Phase II Results
Mike Havrilla • Thu, Jun 21, 2012 • 5 Comments
Potential Golden Eggs In The Basket Of Neptune Technologies & Bioresources
E. Michael Greenberg • Tue, May 8, 2012 • 5 Comments
Solid Fundamental Bet: Shares Of Marine Omega-3 Phospholipids Leader Ready Climb
M. E. Garza • Thu, Apr 26, 2012 • 21 Comments
2 Big Board Biotech Breakout Candidates With Reasons To Run
MarketScanners • Thu, Apr 19, 2012 • 2 Comments
Krill Oil Based Drug Candidate Could Unseat Glaxo's Blockbuster Lovaza
M. E. Garza • Thu, Apr 5, 2012 • 9 Comments
Neptune: Going All Out For The Krill With Its NKO Punch
Michael Morhamus • Wed, Apr 4, 2012 • 13 Comments
With Neptune, Opportunity Is Knockin'
Rob Goldman • Mon, Mar 19, 2012 • 7 Comments
Whether Neptune Can Overcome Market Weigh-Down And Deliver On Milestones
M. E. Garza • Wed, Sep 28, 2011 • 5 Comments
Neptune Has Moved Beyond Downward Catalysts
M. E. Garza • Fri, Sep 16, 2011 • 4 Comments
Neptune More Attractive After Recent Developments
M. E. Garza • Tue, Jul 26, 2011 • 7 Comments
Neptune Technologies: It's All About the Krill Oil
Len Zehr • Wed, Jul 13, 2011 • 9 Comments
Neptune Shares Should Continue to Push Higher on Increased Product Demand
M. E. Garza • Fri, Jun 24, 2011 • 1 Comment
Analyst Predicts Demand and Production Output Will Push Neptune Technologies' Price
M. E. Garza • Wed, May 18, 2011 • 2 Comments

Krill Oil's Omega-3s And CaPre: Brought To You By Acasti
Entry Point • Wed, Apr 3 • 19 Comments
Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity
Life Sciences Report • Fri, Jan 18 • 6 Comments
Do You Have The Guts To Take On Cutting-Edge Biotech Like This VC?
Life Sciences Report • Fri, Dec 14, 2012 • 5 Comments
Applying The Venture Capital Model To Public Companies: Hugh Cleland
Life Sciences Report • Wed, Nov 21, 2012 • 2 Comments
Chen Lin's Key To Huge Biotech Profits: Make It Personal
Life Sciences Report • Mon, Aug 27, 2012 • 8 Comments
4 Bio-Pharmas To Sell Before It Is Too Late
Joe Springer • Fri, Aug 24, 2012 • 93 Comments
Derivative Trades On FDA Approval Events
Red Acre Investments • Mon, Aug 20, 2012 • 24 Comments
1 Rallying Bio/Pharma To Sell, 5 That Look To Keep Rallying
Joe Springer • Wed, Aug 8, 2012 • 7 Comments
Trading The Top Triglyceride Challengers
Brian L. Wilson • Sun, Jul 15, 2012 • 27 Comments
Bio Pharma Potential Big Movers For Thursday, June 28
Scott Matusow • Thu, Jun 28, 2012 • 15 Comments
Amarin Is Headed For A Bullish Run
Longwood Bulls • Tue, Jun 19, 2012 • 30 Comments
Amarin: Most Undervalued Name In Biotech?
Ross Klosterman • Sun, May 13, 2012 • 54 Comments
Latest Research Suggests Amarin Value Now Higher As It Awaits FDA Approval
Steve Rosenman • Fri, Apr 27, 2012 • 32 Comments
Healthcare Investment Conference Roundup
M. E. Garza • Fri, Jan 13, 2012
Big Healthcare Conference Offers Plenty Of New Plays To Pick From
M. E. Garza • Wed, Sep 21, 2011 • 15 Comments
2 Emerging Biotech Companies That Continue to Attract Attention
M. E. Garza • Mon, May 23, 2011 • 4 Comments

Neptune Technologies & Bioresources' CEO Discusses F3Q13 Results - Earnings Call Transcript
Thu, Jan 17

Neptune Responds to Aker's Continued Attempts to Deflect Attention From Its Sustained Patent Infringement

GlobeNewswire (Wed, 8:30AM)
Class Action Lawsuit Against Neptune Dismissed

GlobeNewswire (Wed, 8:00AM)
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2013 Results

GlobeNewswire (May 9, 2013)
The U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation Based on Neptune & Acasti Complaint

GlobeNewswire (Apr 15, 2013)
Neptune Provides Update on European Patent Dispute and Maintains Its International Patent Strategy

GlobeNewswire (Apr 10, 2013)
Neptune to Present at the Annual ROTH Conference

GlobeNewswire (Mar 14, 2013)
Neptune Obtains a Third U.S. Patent on Phospholipid Compositions, Further Bolstering Neptune's Request for an ITC Investigation

GlobeNewswire (Feb 26, 2013)
Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing

GlobeNewswire (Jan 31, 2013)
Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others

GlobeNewswire (Jan 30, 2013)
Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization

GlobeNewswire (Jan 24, 2013)
Neptune Reports Third Quarter Results and Confirms First Insurance Payment

GlobeNewswire (Jan 15, 2013)
Neptune to Hold Conference Call

GlobeNewswire (Jan 14, 2013)
Neptune to Hold Conference Call

GlobeNewswire (Jan 7, 2013)
Neptune Files for Revocation of Aker's Australian Patents

GlobeNewswire (Dec 21, 2012)
Neptune Comments on Filing of Lawsuit

GlobeNewswire (Dec 20, 2012)
Neptune Announces Royalty Prepayment Agreement With Acasti Pharma Inc.

GlobeNewswire (Dec 4, 2012)
Neptune Files an Opposition Against Aker's Australian Patent Application

GlobeNewswire (Nov 27, 2012)
Neptune to Hold Conference Call

GlobeNewswire (Nov 26, 2012)
Neptune Announces Action Plan to Resume Operations and Supply Customers

GlobeNewswire (Nov 26, 2012)
Neptune is Actively Working on Action Plan; Sets Up Special Victims' Fund

GlobeNewswire (Nov 16, 2012)

NEPT vs. ETF Alternatives

Company Description

Currently, there's no company description for NEPT.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 11:58 AM Neptune Technologies & Bioresources (NEPT +4.4%) rises after saying a class action lawsuit against the firm and some of its officers has been voluntarily dismissed without prejudice. (PR) 1 Comment [On the Move]
Friday, February 15, 11:08 AM Shares of Neptune Technologies & Bioressources (NEPT +0.8%) return to earth after being up over 8.7% in pre-market trade, after JMP Securities initiated the stock earlier at Outperform with a lofty $6 price target. Comment! [Healthcare, On the Move]
Tuesday, January 15, 8:11 AM Neptune Technologies & Bioressources (NEPT): Revenue of $7.03M (+37% Y/Y) misses by $1.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, December 19, 2012, 2:18 PM Neptune Technologies & Bioressources (NEPT +18%) bounces back after two days of heavy losses, on the back of comments from its CFO that the company expects to resume production of its nutritional supplements next year, with another factory coming on line in about six months. The company's plant in Sherbrooke was destroyed in November by an explosion and fire, killing three workers. 1 Comment [Healthcare, On the Move]
Tuesday, November 27, 2012, 9:22 AM Neptune Technologies & Bioresources (NEPT) -32% premarket as shares resume trading after being halted since Nov. 8 when an explosion and fire destroyed its production plant in Quebec. As part of an action plan to resume operations and supply customers, the nutritional supplement maker will temporarily lay off ~70 workers while management and employees take salary cuts. Comment! [Healthcare, On the Move]
Monday, September 24, 2012, 4:35 PM Shares of Neptune Technologies (NEPT) dip in the post-trading session after the company files a secondary offering to sell an undisclosed number of shares. RBC Capital Markets and JMP Securities will act as joint book-runners. Shares -5% AH. 1 Comment [On the Move]
Friday, September 7, 2012, 2:45 PM Neptune Technologies & Bioressources (NEPT +4.6%) moves up after its board approves dividend-in-kind distribution and a record date for a partial spin-off of its NeuroBioPharm business. 2M shares will be allotted to shareholders of record as of October 15. Each unit will consist of one class A subordinate voting share of NeuroBio and two warrants. Comment! [Healthcare, On the Move]
Thursday, October 6, 2011, 12:19 PM Neptune Technologies (NEPT +9.5%) trades higher after filing a patent infringement suit against Aker Biomarine ASA, Schiff Nutritional International (WNI +0.4%) and a number of other firms. The suit alleges that the companies are violating it's recently issued omega-3 composition patent. 1 Comment [Healthcare, On the Move]

Joe Springer
$VVUS $SPPI $OMPI $ARIA $PSTI $NEPT $IBIO $CRTX $AMGN Got one warning about Bios coming, some that rallied: http://seekingalpha.com/a/gxpr
8/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I have a new YouTube video up at http://bit.ly/NuYHB0 $ATRS, $AMRN, $HZNP, $OMPI, $SGYP, NEPT
7/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
NEPT Just FYI: Nature. 2011 Apr 7;472(7341):57-63. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
7/5/12
Reply (3)

• !Report Abuse
View all 3 replies
The Scientist: Krill oil contains phosphatidylcholine, which can cause heart disease, according to this paper.
7/6/12
• !Report Abuse
Noreika: Nice find Sci! Damn, guess I won't be buying krill oil tablets at the vitamin shoppe anymore. I'll just stick to the Omegas.
7/17/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Neptune Technologies & Bioresources, Inc. (NEPT) $4.37 a share, market cap: $215.65M pps shorterm target opinion: $5.25
6/28/12
Reply (2)

• !Report Abuse
View all 2 replies
jakerogers77: Thanks for the alert Scott.
6/28/12
• !Report Abuse
DANDISIK: Scott, I see that $NEPT reached a 52 week high today at $4.84 a share.
6/28/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$NEPT is my next pick. DISCLOSURE: MY pops owns a few shares of it. Articles coming. my opinion short term target = $5.50 1 day to 3 months
6/27/12
Reply (1)

• !Report Abuse
View all 1 replies
mojojojo1: opened postion yesterday . Will be putting in a tight stop loss today. Best of luck to us
6/27/12
• !Report Abuse
Add a reply...

140 characters

johnjail
AND WITH A NEW NRK AMBASSADOR LIKE JOHN ELWAY $NEPT SALES COULD BOOST FASTLY :)
4/20/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man's Evil Twin: You had me at John Elway. I bought NEPT fastlier than a sales boost.
4/20/12
• !Report Abuse
johnjail: I think they have a very good product, and the world is full of people with high cholesterol!
4/22/12
• !Report Abuse
Add a reply...

140 characters

johnjail
http://bit.ly/It1Ujj IF THIS RESEARCH IS RIGHT I THINK $NEPT WILL SEE HUGE REVENUE OVER THE NEXT MONTHS/YEARS...
4/20/12
Reply (3)

• !Report Abuse
View all 3 replies
johnjail: http://seekingalpha.com/a/ayh5
4/21/12
• !Report Abuse
johnjail: NICE! I M LONG ON NEPT, I THINK WE HAVE TO WAIT Q2 AND Q3 REVENUES FOR SEE HUGE GAINS. I INVEST ONLY FOR MEDIUM AN LONG TIME, NO SHORT ;)
4/21/12
• !Report Abuse
Add a reply...

140 characters

dinko1982
NEPT has got great potential!
3/24/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

HowardGroup
$NEPT - Neptune - Dr. Oz says Krill Omega 3 is Superior to Fish Oil http://bit.ly/vGmrMu
11/23/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Article on krill oil NEPT. Wang Z et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-63
8/2/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

The Scientist
NEPT Just FYI: Nature. 2011 Apr 7;472(7341):57-63. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
7/5/12
Reply (3)

• !Report Abuse
View all 3 replies
The Scientist: Krill oil contains phosphatidylcholine, which can cause heart disease, according to this paper.
7/6/12
• !Report Abuse
Noreika: Nice find Sci! Damn, guess I won't be buying krill oil tablets at the vitamin shoppe anymore. I'll just stick to the Omegas.
7/17/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Neptune Technologies & Bioresources, Inc. (NEPT) $4.37 a share, market cap: $215.65M pps shorterm target opinion: $5.25
6/28/12
Reply (2)

• !Report Abuse
View all 2 replies
jakerogers77: Thanks for the alert Scott.
6/28/12
• !Report Abuse
DANDISIK: Scott, I see that $NEPT reached a 52 week high today at $4.84 a share.
6/28/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$NEPT is my next pick. DISCLOSURE: MY pops owns a few shares of it. Articles coming. my opinion short term target = $5.50 1 day to 3 months
6/27/12
Reply (1)

• !Report Abuse
View all 1 replies
mojojojo1: opened postion yesterday . Will be putting in a tight stop loss today. Best of luck to us
6/27/12
• !Report Abuse
Add a reply...

140 characters

johnjail
AND WITH A NEW NRK AMBASSADOR LIKE JOHN ELWAY $NEPT SALES COULD BOOST FASTLY :)
4/20/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man's Evil Twin: You had me at John Elway. I bought NEPT fastlier than a sales boost.
4/20/12
• !Report Abuse
johnjail: I think they have a very good product, and the world is full of people with high cholesterol!
4/22/12
• !Report Abuse
Add a reply...

140 characters

johnjail
http://bit.ly/It1Ujj IF THIS RESEARCH IS RIGHT I THINK $NEPT WILL SEE HUGE REVENUE OVER THE NEXT MONTHS/YEARS...
4/20/12
Reply (3)

• !Report Abuse
View all 3 replies
johnjail: http://seekingalpha.com/a/ayh5
4/21/12
• !Report Abuse
johnjail: NICE! I M LONG ON NEPT, I THINK WE HAVE TO WAIT Q2 AND Q3 REVENUES FOR SEE HUGE GAINS. I INVEST ONLY FOR MEDIUM AN LONG TIME, NO SHORT ;)
4/21/12
• !Report Abuse
Add a reply...

140 characters

NEPT Neptune Technologies & Bioresources Inc

NEPT

Neptune Technologies & Bioresources Inc